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TRPC6 counteracts TRPC3-
Nox2 protein complex leading to 
attenuation of hyperglycemia-
induced heart failure in mice
Sayaka Oda1,2, Takuro Numaga-Tomita1,2, Naoyuki Kitajima1,3, Takashi Toyama1,3,4,  
Eri Harada5,6, Tsukasa Shimauchi1,3, Akiyuki Nishimura1,2, Tatsuya Ishikawa3,5,6, 
 Yoshito Kumagai4, Lutz Birnbaumer7,8 & Motohiro Nishida1,2,3,9
Excess production of reactive oxygen species (ROS) caused by hyperglycemia is a major risk factor for 
heart failure. We previously reported that transient receptor potential canonical 3 (TRPC3) channel 
mediates pressure overload-induced maladaptive cardiac fibrosis by forming stably functional complex 
with NADPH oxidase 2 (Nox2). Although TRPC3 has been long suggested to form hetero-multimer 
channels with TRPC6 and function as diacylglycerol-activated cation channels coordinately, the role 
of TRPC6 in heart is still obscure. We here demonstrated that deletion of TRPC6 had no impact on 
pressure overload-induced heart failure despite inhibiting interstitial fibrosis in mice. TRPC6-deficient 
mouse hearts 1 week after transverse aortic constriction showed comparable increases in fibrotic gene 
expressions and ROS production but promoted inductions of inflammatory cytokines, compared to 
wild type hearts. Treatment of TRPC6-deficient mice with streptozotocin caused severe reduction of 
cardiac contractility with enhancing urinary and cardiac lipid peroxide levels, compared to wild type 
and TRPC3-deficient mice. Knockdown of TRPC6, but not TRPC3, enhanced basal expression levels 
of cytokines in rat cardiomyocytes. TRPC6 could interact with Nox2, but the abundance of TRPC6 
was inversely correlated with that of Nox2. These results strongly suggest that Nox2 destabilization 
through disrupting TRPC3-Nox2 complex underlies attenuation of hyperglycemia-induced heart failure 
by TRPC6.
Heart failure is one of the major leading causes of morbidity and mortality in worldwide. Oxidative stress caused 
by excess accumulation of reactive oxygen species (ROS) have been suggested to mediate the development of struc-
tural and morphological changes of the heart (cardiac remodeling) induced by several risk factors including dia-
betic mellitus, hypertension and myocardial infarction1, in part through oxidative post-translational modification 
of intracellular signaling proteins2. The ROS target sulfur-containing amino acids (methionine and cysteine) on 
specific proteins that are found at active or allosteric sites of effector proteins3. In the heart, there are two major 
ROS-producing pathways: the mitochondrial electron transport chain and the enzymatic functions of NADPH 
oxidase (Nox). Mitochondria are definitely the major source of ROS production involved in the pathogenesis of 
heart failure4, but several studies have shown that inhibition of the Nox2 enzyme or Nox2 activators, such as Rac1 
and p47phox, suppresses oxidative stress and cardiac dysfunction in mice with heart failure5. Upregulation of Nox2 
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protein has been reported to participate in cardiac fibrosis during the development of diabetic cardiomyopathy6. As 
ROS also induce mitochondrial superoxide production, so termed ‘ROS-induced ROS release (RIRR)’7, Nox2 may 
act as a primary source of ROS production and amplify RIRR signaling in heart by increasing Nox2 protein stability.
Transient receptor potential (TRP) family proteins, first described in a Drosophila visual transduction muta-
tion trp, comprise 28 mammalian cation channels expressed in almost every tissue8. Among them, canonical 
TRP subfamily (TRPC) proteins, two diacylglycerol (DAG)-activated TRPC members (TRPC3 and TRPC6), 
have been implicated in the development of pathological cardiac remodeling9. TRPC3 and TRPC6 preferentially 
form hetero-tetramer channels10 and coordinately participate in angiotensin II-induced hypertrophic growth 
of neonatal rat cardiomyocytes (NRCMs)11 and pressure overload-induced cardiac hypertrophy in mice12. 
Cardiomyocyte-specific expression of TRPC3 and TRPC6 showed higher sensitivity to pressure overload-induced 
cardiac hypertrophy13, 14 and pharmacological inhibition5, 12, 15 or genetic deletion12, 16 of TRPC3 and TRPC6 
attenuates heart failure in mice. We have recently reported using TRPC3-deficient mice that selective inhibition of 
TRPC3 is sufficient to attenuate pathological cardiac remodeling in mice17, 18. TRPC3 was found to positively reg-
ulate ROS signaling through increasing Nox2 protein stability by forming a protein complex with Nox2, support-
ing the pathological importance of TRPC3 in ROS-dependent heart failure. However, whether TRPC6 inhibition 
is sufficient to improve heart failure is still obscure. TRPC6 has been also reported to participate in pathological 
cardiac remodeling in mice with deletion of Klotho, a membrane protein predominantly produced in the kidney 
that exerts some antiaging effects19. In contrast, TRPC6 reportedly participates in physiological wound healing16 
and negatively regulates formation of TRPC3-Nox2 complex in HEK293 cells17. Physiological roles of TRPC6 
have been extensively studied in the kidney, but both constitutively active and dominant negative mutants of 
TRPC6 exacerbated renal dysfunctions20. This implies that TRPC6 contributes to both adaptive and maladaptive 
responses against environmental stress.
In this study, we demonstrate that deletion of TRPC6 failed to suppress pressure overload-induced heart fail-
ure as well as oxidative stress, despite significant attenuation of cardiac fibrosis in mice. TRPC6 deletion promotes 
induction of inflammatory cytokine productions in pressure-overloaded mouse hearts. In addition, hypergly-
cemia induced by the treatment with streptozotocin (STZ), a compound that has a preferential toxicity toward 
pancreatic β cells, is shown to upregulate TRPC6 in mouse heart, and that the upregulated TRPC6 negatively 
regulates STZ-induced oxidative stress through destabilizing Nox2 protein by counteracting the formation of the 
stable TRPC3-Nox2 complex.
Results
Deletion of TRPC6 attenuates pressure overload-induced fibrosis but not cardiac dysfunction 
and fibrotic gene expressions in mice. We first investigated whether deletion of TRPC6 also attenuates 
pressure overload-induced heart failure using TRPC6-deficient (TRPC6(−/−)) mice. Pressure overload induced by 
transverse aortic constriction (TAC) caused severe increases in heart weight as well as myocardial cell size in both 
wild type (WT) and TRPC6(−/−) mice (Fig. 1a,b). TAC for 6 weeks caused severe deposition of collagen type I and 
type III in the interstitial area in WT hearts, and the extent of fibrosis was well correlated with that of hypertrophy 
(Fig. 1c,d). Surprisingly, TRPC6 deletion significantly suppressed fibrosis but not left ventricular (LV) dysfunc-
tion induced by pressure overload (Fig. 1c–e, Table 1). In contrast, increases in mRNA expression of fibrotic 
genes caused by 1-week TAC were never suppressed in TRPC6(−/−) hearts, neither were those of hypertrophic 
genes (Fig. 1f). A previous report suggests that TRPC6 is highly expressed in cardiac fibroblasts and functions as 
a key mediator of transdifferentiation into myofibroblasts16. In agreement, the TAC-induced increases in mRNA 
expressions of α-smooth muscle actin, a reliable differentiation marker of cardiac fibroblast, were completely sup-
pressed by TRPC6 inhibition (Fig. 1f). These results suggest that TRPC6 inhibition in cardiac fibroblasts attenu-
ates pressure overload-induced fibrosis in mice, while TRPC6 inhibition in cardiomyocytes results in induction 
of cardiac dysfunction after pressure overload in mice.
Inhibition of TRPC6 attenuates cardiac fibrosis but not ROS production induced by pressure 
overload in mice. We next investigated whether inhibition of TRPC6 in cardiomyocytes enhances inflam-
matory response in pressure-overloaded mouse hearts. The mRNA expression levels of interleukin (IL)1β and 
tumor necrosis factor (TNF)α in TAC-operated TRPC6(−/−) hearts were significantly higher than those in WT 
and TRPC3(−/−) hearts (Fig. 2a), indicating enhancement of inflammatory cytokine production by TRPC6 inhi-
bition. Oxidative stress due to increased Nox2 activity has been implicated in sepsis-induced cardiac inflamma-
tion21, and TRPC3 positively regulates ROS signaling through stabilizing and activating Nox2 in rodent heart17. 
However, we previously confirmed that Nox2 expression levels were not enhanced in pressure-overloaded 
TRPC6(−/−) hearts and TRPC6 apparently has no impact on Nox2 stability and activity in rodent cardiomyocytes. 
Therefore, we examined whether inhibition of TRPC6 promotes ROS production from the heart. In order to 
reduce the number of animal experiment, we developed a new method to evaluate cardiac ROS production indi-
rectly by measuring ROS-dependent oxidative modification of cysteine thiol on plasma proteins in arterial blood. 
Using biotin-PEAC5-maleimide (BPM) as a competitive electrophile to react with free cysteine thiol (Fig. 2b), we 
found that the intensity of a single band below 30 kDa observed in sham-operated heart was dramatically reduced 
in TAC-operated heart (Fig. 2c). Mass spectroscopic analysis with Mascot software revealed that this protein was 
identified as glutathione peroxidase 3 (Gpx3), a plasma-specific enzyme that reduces lipid hydroperoxides and 
hydrogen peroxide22 (Supplementary Fig. 1). Using BPM-dependent modification of Gpx3 (BPM-Gpx3) as an 
indirect marker of reducing status in blood, we found that TAC significantly reduced BPM-Gpx3 band intensity 
in the plasma from WT mice, which was well correlated with the severity of fibrosis (Fig. 2d–f). BPM-Gpx3 inten-
sities were higher in the plasma from TAC-operated TRPC3(−/−) mice, suggesting the reduction of oxidative stress 
in the artery. However, BPM-Gpx3 intensities were also reduced in the plasma from TRPC6(−/−) mice to the same 
extent as that from WT mice. These results suggest that suppression of pressure overload-induced cardiac fibrosis 
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Figure 1. TRPC6 deletion attenuates pressure overload-induced cardiac fibrosis but not fibrotic gene 
expression in mice. (a) Heart weight (HW) /body weight (BW) ratio in WT and TRPC6(−/−) mice 6 weeks after 
TAC. WT- TAC(−) (sham) (n = 6), TRPC6(−/−)-sham (n = 6), WT-TAC (n = 13), TRPC6(−/−)-TAC (n = 11). (b) 
Representative images of wheat germ agglutinin (WGA) staining for cross-sectional areas (CSA) measurement 
6 weeks after TAC (left). Green; WGA, blue; DAPI. Quantitative results are shown in right panel. WT-sham 
(n = 6), TRPC6(−/−)-sham (n = 6), WT-TAC (n = 13), TRPC6(−/−)-TAC (n = 11). (c,d) TRPC6 contributes 
to TAC induced cardiac fibrosis. (c) Representative images of picrosirius red staining 6 weeks after TAC and 
results of interstitial fibrosis 6 weeks after TAC. WT-sham (n = 6), TRPC6(−/−)-sham (n = 6), WT-TAC (n = 13), 
TRPC6(−/−)-TAC (n = 11). (d) Relationship between fibrosis and hypertrophy 6 weeks after TAC. WT-sham 
(n = 6), TRPC6(−/−)-sham (n = 6), WT-TAC (n = 13), TRPC6(−/−)-TAC (n = 11). (e) Absence of TRPC6 does 
not affect pressure overload-induced LV dysfunction. LV end-diastolic pressure (LVEDP; left), LV end-systolic 
pressure (LVESP; middle) and LV dP/dtmax (right) in mice 6 weeks after TAC. WT-sham (n = 6), TRPC6(−/−)-
sham (n = 6), WT-TAC (n = 13), TRPC6(−/−)-TAC (n = 11). (f) Expression levels of hypertrophy-related and 
fibrosis-related mRNAs in mouse hearts 1 week after TAC. WT-sham (n = 3), other groups (n = 4 each). Error 
bars, s.e.m. *P < 0.05, **P < 0.01. Results of WT mice were the same as those reported previously17, 18.
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by TRPC6 inhibition is absolutely independent of ROS production, and that suppression of fibrosis compensa-
tively promotes pressure overload-induced inflammatory cytokine expressions in mouse hearts.
Inhibition of TRPC6 exacerbates STZ-induced cardiac dysfunction. Diabetes mellitus is one 
of the most important risk factors for heart failure and major cause of increased morbidity and mortality23. 
Inflammatory mechanisms, including oxidative stress and cytokine productions have been proposed to partic-
ipate in the cardiovascular diabetic complication23–25. Treatment with STZ increased mortality rate in both WT 
and TRPC6(−/−) mice compared to TRPC3(−/−) mice (Fig. 3a), although all mice showed significant increases 
in blood glucose levels at the same extent (Fig. 3b). The STZ treatment had no impact on heart weight in WT, 
TRPC3(−/−) and TRPC6(−/−) mice (Fig. 3c), while LV contractility was significantly reduced in STZ-treated 
TRPC6(−/−) mice (Fig. 3d,e). Treatment of all mice with STZ never caused apparent structural remodeling such 
as hypertrophy and fibrosis (Fig. 3f,g), but it significantly increased urinary malondialdehyde (MDA) concen-
tration in TRPC6(−/−) mice compared to those in WT and TRPC3(−/−) mice (Fig. 3h). Accordingly, TRPC6 
deletion significantly increased plasma levels of total cholesterol (TCHO) and high density lipoprotein choles-
terol (HDLC), and urinary protein, aldosterone and corticosterone levels induced by STZ treatment (Table 2). 
Cardio-renal relationships have now attracted attention as an important mechanism underlying maintenance 
and transfiguration of cardiac homeostasis. These results strongly suggest that TRPC6 deletion exacerbates not 
only hyperglycemia-induced cardiac dysfunction but also renal dysfunction in mice. Treatment with STZ at 
lower dose (50 mg/kg) failed to cause cardiac dysfunction in TRPC6(−/−) mice despite significant increase in 
blood glucose level equivalent to that in high-dose STZ-treated mice (>400 mg/dl), but significantly potentiated 
hyperglycemia-induced increase in cardiac MDA concentration in WT hearts (Fig. 3i). These results indicate that 
inhibition of TRPC6 exacerbates diabetic heart failure induced by STZ in mice.
Hyperglycemia-induced TRPC6 upregulation reduces risk for diabetic heart failure by coun-
teracting TRPC3-Nox2 protein complex. We next examined whether TRPC6 negatively regulates 
Nox2 stability through disrupting TRPC3-Nox2 complex in diabetic mouse hearts. Immunoprecipitation anal-
ysis using myc-tagged p22phox (Myc-p22phox), an essential partner of Nox2 to form stable heteromeric complex, 
revealed that Nox2 protein could interact with TRPC6 as well as TRPC3 (Fig. 4a). However, we previously 
reported that co-expression of TRPC6 with TRPC3 and Nox2 canceled TRPC3-dependent Nox2 stabilization 
in HEK293 cells17. We also confirmed that overexpression of TRPC6 alone had no impact on basal Nox2 sta-
bility in flag-tagged Nox2 (Flag-Nox2)-expressing HEK293 cells, excluding the possibility that TRPC6 itself 
directly destabilize Nox2 protein (Fig. 4a,b). In addition, the Nox2 upregulation via formation of TRPC3-EGFP 
/ Flag-Nox2 protein complex was significantly suppressed by overexpression of pore-dead (with deleted LFW 
motif)10 dominant negative mutant of TRPC6 (TRPC6-DN), as well as wild type TRPC6 (TRPC6-WT) (Fig. 4c). 
These results strongly suggest that TRPC6 counteracts the TRPC3-Nox2 protein complex to destabilize Nox2 
protein. Hyperglycemia induced by STZ significantly increased mRNA expression level of TRPC6, but not 
that of TRPC3, in mouse heart (Fig. 4d). The abundance of Nox2 protein was decreased by STZ treatment in 
WT hearts (Fig. 4e). Furthermore, immunoprecipitation analysis revealed that destabilization of the Nox2 in 
TRPC3-EGFP and Myc-Nox2-expressing HEK293 cells was correlated with the enhanced expression of TRPC6 
as well as the interaction of TRPC6 with TRPC3 (Fig. 4f). We also confirmed that HEK293 cells co-expressing 
TRPC3-EGFP and TRPC6-DN mutant never showed Ca2+ responses evoked by 1-oleoyl-2-acetyl-sn-glycerol 
(OAG), a DAG-derivative that can directly increase TRPC6 channel activity (Fig. 4g). These results suggest that 
TRPC6 negatively regulates hyperglycemia-induced Nox2 stabilization through counteracting and disrupting 
formation of TRPC3-Nox2 stable protein complex in heart.
TRPC6 negatively regulates high glucose-dependent basal cytokine production inde-
pendently of Ca2+ channel activity in NRCMs. We further examined whether TRPC6 negatively 
regulates hyperglycemia-induced inflammatory cytokine production in NRCMs. As NRCMs are normally cul-
tured in high-glucose (25 mM) medium, we first investigated whether TRPC6 expression level is upregulated in 
NRCMs with high-glucose medium compared to those with low-glucose (5.5 mM) medium, because NRCMs 
in low-glucose medium are vulnerable to hypoxia-induced ROS-mediated mitochondrial injury26. As expected, 
TRPC6 mRNA expression level is higher in NRCMs with high glucose medium than those with low-glucose 
medium (Fig. 5a). In addition, knockdown of TRPC6, but not TRPC3, significantly increased basal mRNA 
WT sham 
(n = 6)
WT TAC 
(n = 13)
TRPC6 (−/−) 
sham (n = 6)
TRPC6 (−/−) 
TAC (n = 11)
Heart Rate (bpm) 410 ± 6 393 ± 6 413 ± 5 390 ± 5
LVESP (mmHg) 135 ± 1 180 ± 10 ** 146 ± 4 195 ± 6 **,†
LVEDP (mmHg) 0.8 ± 0.5 5.4 ± 0.7 ** 0.7 ± 1.3 5.5 ± 1.0 **,†
LVdP/dtmax (mmHg/sec) 10503 ± 531 8552 ± 282 ** 10162 ± 100 9023 ± 270 *
LVdP/dtmin (mmHg/sec) 7298 ± 104 6598 ± 381 7397 ± 161 6269 ± 409
Tau (msec) 12.5 ± 0.3 16.0 ± 0.9 12.2 ± 0.3 19.3 ± 1.4 **,†
Table 1. Cardiac parameters measured by Millar Catheter. LVESP, left ventricular end systolic pressure; LVEDP, 
left ventricular end diastolic pressure; dP/dtmax, maximal rate of pressure development; dP/dtmin, maximal rate 
of decay of pressure; Tau, monoexponential time constant of relaxation. *P < 0.05, **P < 0.01 vs WT sham, 
†P < 0.01 vs TRPC6 (−/−) sham. Results of WT mice were the same as those reported previously17.
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Figure 2. TRPC6 deletion enhances pressure overload-induced expressions of inflammatory cytokine mRNAs 
in mouse hearts. (a) Expression levels of TNFα and IL1β mRNAs in mouse hearts 1 week after TAC. WT 
sham (n = 3), other groups (n = 4 each). (b) Schema for the principle of BPM labeling assay. (c) Representative 
images of western blotting using anti-biotin-HRP and coomassie brilliant blue (CBB) staining of gels loaded 
with plasma samples from mice 6 weeks after TAC. Full-length blots and gels are presented in Supplementary 
Fig. 2a. (d,e) Representative western blot (d) and quantification (e) of BPM-modified and total Gpx3 in mouse 
plasma 6 weeks after TAC. WT-sham (n = 6), TRPC3(−/−)-sham (n = 6), TRPC6(−/−)-sham (n = 6), WT-TAC 
(n = 13), TRPC6(−/−)-TAC (n = 12), TRPC6(−/−)-TAC (n = 11). Full-length blots of all samples are presented in 
Supplementary Fig. 2b. (f) Relationship between fibrosis and levels of BPM-modified Gpx3. WT-sham (n = 6), 
TRPC3(−/−)-sham (n = 6), TRPC6(−/−)-sham (n = 6), WT-TAC (n = 13), TRPC3(−/−)-TAC (n = 12), TRPC6(−/−)-
TAC (n = 11). Error bars, s.e.m. *P < 0.05, **P < 0.01.
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Figure 3. Deletion of TRPC6 but not TRPC3 promotes streptozotocin(STZ)-induced cardiac dysfunction 
in mice. (a) Survival rate of STZ-treated mice (n = 10 each). (b) Concentration of blood glucose (n = 3 each). 
(c) HW/BW ratio of mice with or without STZ treatment for 4 weeks (n = 3 each). (d,e) Absence of TRPC6 
exacerbates STZ-induced LV dysfunction. Time courses of fractional shortening (FS) (d) and LVdP/dtmax at 
the end of 4-week STZ treatment (e) (n = 3 each). (f,g) Representative images of hematoxylin & eosin-stained 
LV sections to visualize cross sectional area of cardiomyocytes (f) and magnified endocardial (left) and 
epicardial (right) regions of LV sections stained with Masson Trichrome (g). (h,i) Absence of TRPC6 enhances 
hyperglycemia-induced ROS production. Accumulation of malondialdehyde (MDA) in urine (h) and heart (i) 
(n = 3 each). Error bars, s.e.m. *P < 0.05,**P < 0.01.
www.nature.com/scientificreports/
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expression levels of IL1β and TNFα in NRCMs with high-glucose medium (Fig. 5b). Knockdown of TRPC6 
compensatively increased TRPC3 mRNA expression level, as well as ROS production and Nox2 protein abun-
dance in NRCMs when cultured in the presence of high glucose (Fig. 5c–e). These results strongly suggest that 
high-glucose-dependent TRPC6 upregulation negatively regulates basal inflammatory cytokine production 
through inhibiting TRPC3-Nox2-mediated ROS production in NRCMs.
TRPC6 channel activity is reportedly enhanced by mechanical stress27, 28. Mechanical stretching of NRCMs 
induced by replacement of normal high-glucose solution to hypotonic solution increased intracellular Ca2+ con-
centration ([Ca2+]i), while this [Ca2+]i increase was not suppressed by knockdown of TRPC3 or TRPC6 (Fig. 5f). 
As the basal [Ca2+]i in TRPC6-silenced NRCMs were similar with that in control NRCMs, this result indicates 
that high glucose upregulates TRPC6 level but never increases TRPC6 channel activity in NRCMs, and suggests 
that TRPC6 upregulation, but not TRPC6 channel activity, underlies high-glucose-dependent negative regulation 
of basal inflammatory cytokine production in NRCMs.
Discussion
The TRPC family includes seven members, and is divided into two groups based on structural and functional 
similarities: TRPC1/4/5, which are sensitive to inositol-1,4,5-trisphosphate (IP3)-mediated Ca2+ release from 
IP3-sensitive Ca2+ store followed by capacitative Ca2+ entry triggered by Ca2+ depletion in the intracellular 
Ca2+ store, and TRPC3/6/7, which are sensitive to DAG. TRPC429 and TRPC530 are activated by intracellular 
Ca2+, TRPC1 is activated by store depletion30, and TRPC4 and TRPC5 are also activated by DAG in an Na+/
H+ exchanger regulatory factor-dependent manner31. TRPC6 protein preferentially associates with TRPC3 and 
TRPC7 proteins to form DAG-activated homo- and/or hetero-multimer channels32. Although TRPC3 (as well as 
TRPC7) and TRPC6 are 75% identical and higher degree of functional similarity, TRPC3 and TRPC6 differ sub-
stantially in their basal channel activities. TRPC6 is a tightly regulated receptor-activated cation channel33, while 
TRPC3 and TRPC7 display considerable constitutive activity34. A discrepant N-linked glycosylation pattern has 
been reported to determine the differences between basal TRPC3 and TRPC6 channel activities33. TRPC3, but 
not TRPC6, acts as a signaling platform through interacting with phospholipase C35 and protein kinase C36 to 
amplify agonist-induced intracellular signaling pathways. TRPC6(−/−) mice were originally shown an increased 
vascular smooth muscle contractility through compensative upregulation of TRPC337, suggesting that TRPC6 
has distinct nonredundant roles in the control of vascular smooth muscle tone. Using TRPC6-deficient 129/Sv 
background mice, we found that TRPC6 deletion failed to suppress pressure overload-induced LV dysfunction 
as well as oxidative modification of plasma Gpx3 protein, despite significant suppression of interstitial fibrosis 
(Figs. 1 and 2). This result suggests that inhibition of cardiac fibroblast differentiation into myoblast is insuffi-
cient to suppress heart failure. In addition, deletion of TRPC6 promoted STZ-induced sudden death as well as 
cardiac dysfunction and oxidative stress (Fig. 3). High glucose upregulates TRPC6 and destabilize Nox2 protein 
in NRCMs, and knockdown of TRPC6, but not TRPC3, enhanced basal ROS production as well as inflamma-
tory cytokine production, independently of TRPC6 channel activity (Fig. 5). These results strongly suggest that 
TRPC6 negatively regulates ROS signaling through counteracting the TRPC3-Nox2 complex in rodent cardio-
myocytes (Fig. 6).
The mRNA expression levels of IL1β and TNFα were upregulated in TAC-operated TRPC6(−/−) hearts com-
pared to those in WT and TRPC3(−/−) hearts (Fig. 2). It is well known that inductions of these genes depend on 
nuclear factor (NF)-κB activity. We have previously reported that purinergic P2Y6 receptor-α subunit of G12/13 
(Gα12/13) protein signaling initiates TAC-induced cardiac fibrosis in mice38, and the activation of Gα13 increases 
expression of these cytokines in a NF-κB-dependent manner in rat cardiac fibroblasts39. The Gα13 activation also 
increases TRPC6 expression levels, while the upregulated TRPC6 proteins negatively regulate fibrotic responses 
of cardiac fibroblasts40. These findings suggest that Gα12/13-mediated NF-κB-dependent signaling pathway may 
be potentiated in TAC-operated TRPC6(−/−) hearts.
Focusing on the redox status in the blood of mice with heart failure, we demonstrated that oxidative modifi-
cation of plasma Gpx3 protein was well correlated with the severity of maladaptive cardiac remodeling induced 
by pressure overload (Fig. 2). Because TRPC6 deletion suppressed cardiac fibrosis without suppressing Gpx3 
oxidation, the extent of Gpx3 oxidative modification seems not necessarily correlated with the severity of inter-
stitial fibrosis in mice. However, oxidative modification of Gpx3 could be a good marker for estimating ROS 
WT STZ(−) 
(n = 3)
WT STZ( + ) 
(n = 3)
TRPC3(−/−) 
STZ(−) 
(n = 3)
TRPC3(−/−) 
STZ( + ) 
(n = 3)
TRPC6(−/−) 
STZ(−) 
(n = 3)
TRPC6(−/−) 
STZ( + ) (n = 3)
plasma
GLU (mg/dl) 140 ± 14 511 ± 51** 153 ± 9 454 ± 34** 133 ± 21 445 ± 32**
TCHO (mg/dl) 69 ± 6 146 ± 26 59 ± 6 131 ± 14 62 ± 10 203 ± 62†
HDLC (mg/dl) 61 ± 5 134 ± 21 59 ± 4 105 ± 2 51 ± 7 166 ± 48*,†
urine
Protein (mg/mg 
Cre) 70.4 ± 10.6 111.5 ± 15.1 46.2 ± 1.2 128.5 ± 14.9 38.9 ± 4.6 267.7 ± 92.4
*
Aldosterone (ng/
mg Cre) 8.2 ± 0.22 62.0 ± 17.3 16.5 ± 5.0 41.3 ± 14.1 39.3 ± 19.2 253.8 ± 109.9
*
Corticosterone 
(ng/mg Cre) 56.1 ± 3.4 711.8 ± 261.9 122.3 ± 57.0 259.8 ± 69.1 184.0 ± 39.8 2431.3 ± 941.4
*
Table 2. Results of plasma and urinary parameters in STZ-treated mice. GLU, glucose; TCHO, total cholesterol; 
HDLC, high density lipoprotein cholesterol; Cre, creatinine. *P < 0.05, **P < 0.01 vs WT STZ(−), and †P < 0.05 
vs TRPC6 (−/−) STZ(−).
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Figure 4. Involvement of TRPC6 in hyperglycemia-induced Nox2 downregulation through inhibition of 
the TRPC3-Nox2 complex formation. (a) Interaction of TRPC6-EGFP with Flag-Nox2 and Myc-p22phox in 
HEK293 cells. Immunoprecipitation (IP) was performed using an anti-Myc antibody. Full-length blots are 
presented in Supplementary Fig. 3a. (b) Quantitative results of Nox2 and p22phox protein abundances in input 
samples. (n = 4 each) (c) Effects of expression of TRPC6 (WT or DN) on Nox2 stability in TRPC3-EGFP and 
Flag-Nox2-expressing HEK293 cells (n = 3 each). Full-length blots are presented in Supplementary Fig. 3b. (d) 
Expression levels of TRPC3 and TRPC6 mRNAs in mouse hearts with or without STZ treatment (n = 3 each). 
www.nature.com/scientificreports/
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production in heart through the TRPC3-Nox2 complex, since TRPC3-deficient mice showed a complete reduc-
tion of Gpx3 oxidation as well as fibrosis. As the inhibition of TRPC3, but not TRPC6, actually suppressed pres-
sure overload-induced heart failure, oxidative modification of Gpx3 will be a novel biomarker for diagnosing the 
severity of maladaptive cardiac remodeling.
Gpx3 contains a selenocysteine (Sec) residue at its active center site, and Sec is highly nucleophilic and easily 
react with electrophilic molecules, including peroxide. As the deprivation of this Sec results in reduced Gpx3 
enzymatic activity, electrophilic modification of this Sec will also reduce Gpx3 enzymatic activity. However, we 
could not observe any apparent reduction of plasma peroxidase activity in mice (data not shown). This result 
suggests that BPM does not react with Sec, but may target one of other two cysteine thiols in Gpx3. Further study 
will be necessary to reveal the physiological significance of electrophilic modification of Gpx3 during the devel-
opment of heart failure.
In conclusion, we revealed a new channel activity-independent role of TRPC6 protein in murine cardiac 
pathology. Upregulation of TRPC6 protein destabilizes the TRPC3-Nox2 complex, which leads to prevention of 
ROS production-dependent cardiac dysfunction induced by hyperglycemia. Elucidation of the role of TRPC6 as 
an endogenous negative regulator of ROS signaling deepens the understanding of the molecular diversity and 
function of TRPC channels and will provide a novel therapeutic strategy for heart failure.
Methods
Animals and reagents. All protocols using mice and rats were reviewed and approved by the ethics com-
mittees at the National Institutes of Natural Sciences or the Animal Care and Use Committee, Kyushu University, 
and were performed according to the institutional guidelines concerning the care and handling of experimental 
animals. 129/Sv mice with homozygous deletion of the gene encoding TRPC3 and TRPC6 were provided by the 
Comparative Medicine Branch, National Institute of Environmental Health Sciences, Research Triangle Park, 
North Carolina 27709. Genotyping was performed as previously described32. Mice were maintained in specif-
ic-pathogen-free area under a 12-hour/12-hour light/dark cycle. Sprague-Dawley rats were purchased from Japan 
SLC, Inc. STZ and lipopolysaccharide (LPS) were purchased from Sigma. Alexa Fluor 488-conjugated wheat germ 
agglutinin (WGA) was purchased from Life technologies.
TAC surgery and STZ treatment, and measurement of cardiac functions. Pressure overload was 
induced as described previously5, 17. Male mice, 6–8 weeks old, were used for these experiments. Cardiac pressure 
overload was induced by TAC. Briefly, mice were anesthetized using a mixture of domitor (Zenoaq), midazolam 
(Sando) and butorphanol (Meiji Seika Pharma). After orotracheal intubation and ventilation, an intercostal space 
was opened. The transverse aorta was then exposed and constricted between the brachiocephalic artery and left 
carotid artery to the width of a 27-G needle using a 5–0 silk braid. Sham treatment was performed similarly but 
without constriction of the silk braid.
For the development of diabetic heart failure, male 129/Sv mice (10–12-week-old) were injected intraperito-
neally with STZ (250 mg/kg, dissolved in sodium citrate buffer (0.1 M, pH 4.5)). For cardiac MDA measurement, 
male 129/Sv mice were injected with minimal STZ (50 mg/kg) for 5 successive days, and then, LPS (5 mg/kg) 
dissolved in phosphate buffered saline were injected intraperitoneally in mice 4 weeks after STZ treatment to 
promote hyperglycemia-dependent inflammation. Mice were sacrificed 24 hours after LPS injection.
Measurement of LV functions and biochemical parameters. Echocardiography and catheterization 
were performed as described previously5, 17. Echocardiography was performed using Nemio-XG echocardiogra-
phy (Toshiba) with 14-MHz transducer under anesthesia with isoflurane (induction: 3–4%). LV hemodynamic 
parameters of mice 6-week after TAC or 4-week STZ treatment were assessed using a micronanometer cathe-
ter (Millar 1.4F, SPR 671, Millar Instruments) under anesthesia. Cardiac parameters of WT animals have been 
already reported17.
Measurement of biochemical parameters in plasma glucose (Glucose Pilot, Technicon), total cholesterol, and 
high density lipoprotein cholesterol, and urinary protein (Pierce BCA protein assay kit, Thermo Fisher Scientific), 
urinary aldosterone and corticosterone (Enzyme immunoassay system, Cayman Chemical) were performed as 
described previously41. Blood samples collected from cardiac apex at the time of euthanasia were centrifuged 
(3,000 × g) for 15 min to prepare plasma samples. Plasma total cholesterol (TCHO) and HDL cholesterol (HDLC) 
levels were measured using DRI-CHEM 7000Z (Fuji Film) with slides of TCHO-PIII or HDL-C-PIIID (Fuji Film) 
according to manufacturer’s instruction. Mice were individually placed in metabolic cages (Natsume), and urine 
samples were collected for 24 hours.
Morphological analysis of mouse hearts. Staining of LV sections (3 μm thickness) with hematoxylin 
and eosin, Masson trichrome and picrosirius red were described previously17, 18, 38. To assess CSA of cardiomy-
ocytes, the sections were stained with Alexa Fluor 488-conjugated WGA and DAPI (Dojindo). Three regions 
(e) Nox2 protein abundance in mouse hearts with or without STZ (n = 3 each). Full-length blots are presented 
in Supplementary Fig. 3c. (f) Formation of protein complex among TRPC3-EGFP, Myc-Nox2 and TRPC6-Flag. 
IP was performed using anti-Flag antibody. Full-length blots are presented in Supplementary Fig. 3d. (g) OAG 
(90 µM)-induced Ca2+ responses in HEK293 cells expressing EGFP (−), TRPC3-EGFP (TRPC3), TRPC3-
EGFP and TRPC6-WT-mCherry (TRPC3 + TRPC6(WT)), and TRPC3-EGFP and TRPC6-DN-mCherry 
(TRPC3 + TRPC6(DN)). Averaged time courses (left) and [Ca2+]i increases shown as area under the curve 
(AUC, right) (n = 30 cells). Error bars, s.e.m. *P < 0.05, **P < 0.01.
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Figure 5. Involvement of TRPC6 in TRPC3/Nox2-mediated ROS production. (a) Expression levels of TRPC3 
and TRPC6 mRNAs in NRCMs cultured in low (LG, 5.5 mM) or high (HG, 25 mM) glucose-containing 
medium (n = 3 each). (b) Expression levels of TNFα or IL1β in NRCMs cultured in LG or HG medium (n = 7 
each). (c) Expression levels of TRPC3 and TRPC6 mRNAs in NRCMs transfected with siRNAs. (n = 5 each). 
(d,e) Abundance of Nox2 protein (d) and ROS production (e) in siRNA-transfected NRCMs cultured in LG or 
HG medium (n = 3 each). Full-length blots are presented in Supplementary Fig. 4. (f) Ca2+ responses induced 
by hypotonic stress (70 mM NaCl) in siRNA-transfected NRCMs. Averaged time courses (left) and [Ca2+]i 
increases shown as AUC (right) (n = 45–46 cells). Error bars, s.e.m.*P < 0.05, **P < 0.01.
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were selected at random for each left ventricle, and the average values were calculated using a BZ-II Analyzer 
(Keyence).
Cell cultures and isolation of NRCMs. HEK293 cells were cultured in DMEM supplemented with 10% 
FBS and 1% penicillin and streptomycin. Plasmid DNAs were transfected into HEK293 cells with X-tremeGENE9 
(Roche) according to manufacturer’s instruction. Isolation of NRCMs were performed as described previously17. 
After serum deprivation, NRCMs were cultured in either normal high-glucose DMEM (25 mM) or low glucose 
DMEM (5.5 mM). For protein knockdown, cells were transfected with siRNAs11, 17 (10 nM) using Lipofectamine 
RNAiMAX (Invitrogen) for 72 hours.
Measuring mRNA expression in cells and tissues. Total RNA was isolated from fro-
zen mouse heart samples using an RNeasy Fibrous Tissue Mini Kit (Qiagen) or from cardiomy-
ocytes using an RNeasy Mini Kit (Qiagen) as described previously17. Quantitative real-time PCR 
(qRT-PCR) was performed using Lightcycler® 96 (Roche) with OneStep RT-PCR Kit (Qiagen) or 
KAPA SYBR® FAST qPCR kit (KAPA BIOSYSTEMS). All Taqman probes were purchased from 
Applied Biosystems18. Primers used in qRT-PCR with SYBR Green were as follows: mouse IL1β forward 
Figure 6. Schema of negative crosstalk between TRPC6 and TRPC3-Nox2 complex in cardiomyocytes. In 
resting condition, TRPC3 and TRPC6 channels function independently or coordinately in cardiomyocytes. 
Once hearts are exposed to environmental stresses such as hemodynamic load and hyperglycemia, TRPC3 
forms stable protein complex with Nox2, which evokes aberrant ROS production in cardiomyocytes. In 
contrast, environmental stresses also upregulate TRPC6, which can counteract formation of the TRPC3-Nox2 
complex in cardiomyocytes, leading to Nox2 destabilization, and resulting in negative regulation of ROS 
signaling in heart.
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5′-CACCTTCTTTTCCTTCATCTTTG-3′, reverse 5′-GTCGTTGCTTGTCTCTCCTTGTA-3′; mouse TNFα 
forward 5′-ACTGAACTTCGGGGTGATTG-3′, reverse 5′-GCTTGGTGGTTTGCTACGAC-3′; mouse TRPC6 
forward 5′-GACCGTTCATGAAGTTTGTAGCAC-3′, reverse 5′-AGTATTCTTTGGGGCCTTGAGTCC-3′; 
rodents 18 S ribosomal RNA forward 5′-ATTAATCAAGAACGAAAGTCGGAGGT-3′ ,  reverse 
5′-TTTAAGTTTCAGCTTTGCAACCACACT-3′.
Measurement of intracellular Ca2+ increases and ROS production. Measurement of intracellular 
Ca2+ increases were performed with Fura 2-AM (Dojindo) as previously described42. After aspirating the culture 
medium from the dishes and washing the cells with DMEM, freshly prepared 1 μM Fura 2-AM diluted in DMEM 
was added to the dishes and incubated for 30 min at room temperature. The dye solution was then replaced 
with HEPES-buffered saline solution (HBSS) containing 140 mM NaCl, 5.6 mM KCl, 5.5 mM or 25 mM glucose, 
10 mM HEPES (pH 7.4), 1 mM MgCl2 and 2 mM CaCl2. Fluorescence images were recorded and analyzed using 
a video image analysis system (Metafluor, Molecular Devices). Only NaCl concentration was reduced to 70 mM 
in hypotonic buffer. Dihydroethidium (DHE) staining with NRCMs was performed as previously described5.
Measurement of MDA concentration. Total cardiac and urinary MDA was assessed in mice using a 
Lipid peroxidation (MDA) Assay kit (Abcam) as described previously17. Briefly, frozen mouse heart samples were 
weighed and homogenized in MDA Lysis Buffer and buthylated hydroxytoluene, and the lysates were clarified 
by centrifugation at 13,000 × g for 10 min at 4 °C. Samples of cardiac supernatant and urine samples were then 
allowed to react with thiobarbituric acid reagent at an acidic pH at 95 °C for 1 hour and read at 532 nm using a 
Spectra Max i3 (Molecular Devices). MDA concentrations were estimated using a standard curve derived using 
standard MDA. Total cardiac protein concentration was determined by DCTM protein assay (BIO-RAD).
Western blotting. To analyze expression of endogenous Nox2 in mouse hearts and NRCMs, total membrane 
fraction was isolated as described previously36. Mouse hearts were first powdered in liquid nitrogen and then 
lysed in hypotonic lysis buffer. Co-immunoprecipitation of TRPC6 with Flag-Nox2 and Myc-p22phox was per-
formed as previously described17. Primary antibodies used were; GAPDH (sc-25778), gp91phox (sc-130543), from 
Santa Cruz Biotechnology, Flag M2-HRP (A8592) from Sigma Aldrich, GFP (CHIP grade, ab290) from Abcam, 
Myc-tag (05–742) from Merck and TRPC6 from cell signaling technologies.
Identification of BPM-bound plasma proteins. Competitive BPM labeling assay was per-
formed as described previously43. Briefly, mouse plasma (20 μg of protein) were prepared and mixed with 
biotin-PEAC5-maleimide (BPM, Dojindo) (25 µM) and rocked at 37 °C for 30 min to label cysteine free-thiols 
on proteins. Then the plasma was incubated with Laemmli buffer and boiled at 95 °C for 5 min. The proteins 
were subjected to SDS-PAGE, and BPM-bound proteins were visualized using anti-biotin-HRP-linked antibody 
(#7075, Cell signaling). For identification of Gpx3, the gel was stained with coomasie brilliant blue (Nacalai), 
and then dehydrated by 30% acetonitrile, and proteins were reduced by dithiothreitol (100 mM), alkylated by 
iodoacetamide (100 mM) and digested by Trypsin-Gold (Promega) with protease MAX surfactant (Promega). 
Peptides were analyzed with liquid chromatography–mass spectrometry (EASY-nLC1000 and Orbitrap Elite, 
Thermo). Data were analyzed by Mascot ver.2.5.1 (Matrix science).
Statistical Analysis. Results are presented as the mean ± s.e.m. from at least three independent experi-
ments. Statistical comparisons were made using Student’s t-test (for two groups) or analysis of variance followed 
by Tukey’s post hoc test (for multiple groups). Values of P < 0.05 were considered significant.
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